Option chain shows key data for Aridis Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aridis Pharmaceuticals.

Aridis Pharmaceuticals (OTC:ARDS) Stock, Option Chain

Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABOS

ADES

APLS

APVO

ARDS

ATRO

ATUS

AWIN

BPTS

EOSE

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXPI

FREY

FWBI

GRRR

HCTI

HYPR

ICAD

INOD

IRNT

ISUN

LINK

LIXT

MASI

MBWM

MICS

MNMD

NMTR

NOVN

PACW

PIRS

QBTS

RVYL

SCHW

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SNAX

UTME

Gainers


	Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.


Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Health Care

Pre-Market Outlook

General

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational monoclonal 

Why Are Aridis Pharmaceuticals Shares Moving Higher Today?

HKIT

KPTI

TAOP

TCBP

VAPO

Gainers


	Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company&#39;s main product.


Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket

Comments

Aridis Pharmaceuticals

Aridis Pharmaceuticals (ARDS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga